Compare Cassava Sciences Inc (FLNA) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs PulteGroup, Inc. — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while PulteGroup, Inc. trades at $128.64 (market cap $23.89B). The key difference: PulteGroup, Inc. is far larger — about 449.6× Cassava Sciences Inc's market cap, and PulteGroup, Inc. pays a 0.83% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | PHM | |
|---|---|---|
Market Cap | $53.14M | $23.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $142.56 |
52-Week Low | $1.09 | $108.65 |
Enterprise Value | -$33.43M | $23.84B |
Dividend Yield | — | 0.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
PulteGroup (PHM) trades at $127.11, up 2.05% today, with a bullish technical signal and strong profitability metrics including a 12.14% net margin. Recent earnings show mixed results with a Q3 2025 beat but subsequent misses, while cash flow trends improved in 2025. The stock is near its 52-week high of $144.50, reflecting resilience despite housing market headwinds from rising mortgage rates.
Outlook is cautiously optimistic with a consensus price target of $145.20 offering 14% upside, but risks include margin pressure from discounts and rate buydowns. Investment opportunity hinges on execution amid affordability challenges, with analyst sentiment balanced between buy and hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
